Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer
Authors:
Open Access
- 27 March 2020
- journal article
- research article
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (3)
Abstract
Objectives: The purpose of the present study was to evaluate the prognostic value of a systemic immune-inflammation index (SII) and the relationship between SII and the effectiveness of postoperative treatment in patients with non-small cell lung cancer (NSCLC). Methods: A total of 538 patients diagnosed with NSCLC who had undergone curative surgery were retrospectively enrolled in the study. Clinicopathologic and laboratory variables were collected. SII was defined as neutrophil × platelet/lymphocyte counts. Both univariate and multivariate analyses were performed to analyze the prognostic value of these factors. Results: The preoperative SII level was associated with sex, smoking history, histological type, lesion type, resection type, pathological stage, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), fibrinogen and bone metastasis (P<0.05). The univariate and multivariate analyses revealed that SII was an independent prognostic factor for disease-free survival (DFS, P=0.033) and overall survival (OS, P=0.020). Furthermore, the prognostic value of SII was also verified regardless of the histological type and pathological stage. The subgroup analysis demonstrated that patients with a high SII may benefit from adjuvant therapy (P=0.024 for DFS and P=0.012 for OS). Conclusion: An increased preoperative SII may independently predict the poor DFS and OS in patients with resectable NSCLC. SII may help select NSCLC patients who might benefit from adjuvant chemotherapy.Keywords
This publication has 28 references indexed in Scilit:
- Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysisBreast Cancer Research, 2017
- The impact of the Cancer Genome Atlas on lung cancerTranslational Research, 2015
- Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non‐small cell lung cancer patientsThoracic Cancer, 2015
- Systemic Immune-inflammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte Ratio, Is Useful for Predicting Prognosis in Small Cell Lung CancerThe Tohoku Journal of Experimental Medicine, 2015
- Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular CarcinomaClinical Cancer Research, 2014
- Cancer-related inflammation and treatment effectivenessThe Lancet Oncology, 2014
- 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-upAnnals of Oncology, 2014
- Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganismsNature Reviews Cancer, 2013
- A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studiesThe Lancet, 2012
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNMAnnals of Surgical Oncology, 2010